HRS9531 Injection in Obese Subjects With Heart Failure With Preserved Ejection Fraction

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
This was a multicenter, randomized, double-blind, placebo-parallel-controlled Phase II clinical study to evaluate the efficacy and safety of HRS9531 Injection compared to placebo in obese subjects with heart failure with preserved ejection fraction. A total of 200 obese subjects with heart failure with preserved ejection fraction would be enrolled. Eligible subjects were randomly assigned to either HRS9531 group or placebo group and were treated with HRS9531 injection or placebo, respectively, for 52 weeks.
Epistemonikos ID: 935ea8260b5e0bb0ad5bf46691f4a35d214c9496
First added on: May 16, 2024